236 related articles for article (PubMed ID: 26476120)
21. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
23. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
24. [Guidelines on the early detection of prostate cancer].
Alberts AR; Bokhorst LP; Roobol MJ
Ned Tijdschr Geneeskd; 2015; 159():A8811. PubMed ID: 25898869
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.
Whitson JM; Porten SP; Carroll PR
Nat Rev Urol; 2011 Mar; 8(3):124-5. PubMed ID: 21304508
[No Abstract] [Full Text] [Related]
26. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
[TBL] [Abstract][Full Text] [Related]
27. PSA screening: the USPSTF got it wrong.
Scherger JE
J Fam Pract; 2013 Nov; 62(11):616, 618. PubMed ID: 24288701
[No Abstract] [Full Text] [Related]
28. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum.
Sajid S; Mohile SG; Szmulewitz R; Posadas E; Dale W
Semin Oncol; 2011 Apr; 38(2):309-25. PubMed ID: 21421119
[TBL] [Abstract][Full Text] [Related]
29. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.
Venderbos LD; Roobol MJ
Asian J Androl; 2011 Mar; 13(2):219-24. PubMed ID: 21297655
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
31. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
32. 'What is this active surveillance thing?' Men's and partners' reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option.
O'Callaghan C; Dryden T; Hyatt A; Brooker J; Burney S; Wootten AC; White A; Frydenberg M; Murphy D; Williams S; Schofield P
Psychooncology; 2014 Dec; 23(12):1391-8. PubMed ID: 24830805
[TBL] [Abstract][Full Text] [Related]
33. Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.
Carter HB
Curr Opin Urol; 2015 May; 25(3):277-82. PubMed ID: 25692722
[TBL] [Abstract][Full Text] [Related]
34. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
35. Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.
Baum N; Levy J
Postgrad Med; 2015 Aug; 127(6):654-9. PubMed ID: 26118565
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer and PSA screening.
Mameghan H
Aust Fam Physician; 1999 Aug; 28(8):777-81. PubMed ID: 10495525
[TBL] [Abstract][Full Text] [Related]
37. Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality.
Labrie F; Cusan L; Gomez JL; Diamond P; Candas B
J Clin Endocrinol Metab; 1995 Jul; 80(7):2002-13. PubMed ID: 7541800
[TBL] [Abstract][Full Text] [Related]
38. [Focal therapy of prostate cancer in Germany].
Apfelbeck M; Herlemann A; Stief CG; Gratzke C
Urologe A; 2016 May; 55(5):584-92. PubMed ID: 27142799
[TBL] [Abstract][Full Text] [Related]
39. Expectant management for men with early stage prostate cancer.
Filson CP; Marks LS; Litwin MS
CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
Dorr VJ; Williamson SK; Stephens RL
Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
